Hengjun He

531 total citations
8 papers, 456 citations indexed

About

Hengjun He is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Hengjun He has authored 8 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Cellular and Molecular Neuroscience and 3 papers in Pharmacology. Recurrent topics in Hengjun He's work include Receptor Mechanisms and Signaling (3 papers), Cannabis and Cannabinoid Research (3 papers) and Neuropeptides and Animal Physiology (3 papers). Hengjun He is often cited by papers focused on Receptor Mechanisms and Signaling (3 papers), Cannabis and Cannabinoid Research (3 papers) and Neuropeptides and Animal Physiology (3 papers). Hengjun He collaborates with scholars based in United States and China. Hengjun He's co-authors include Dana E. Selley, Michael P. Cassidy, Xianglin Shi, Xueguang Zhang, Zhuo Zhang, Ning Gao, Stephen S. Leonard, Liqin Shen, Bing‐Hua Jiang and John W. Huffman and has published in prestigious journals such as Molecular Pharmacology, Bioorganic & Medicinal Chemistry and Bioorganic & Medicinal Chemistry Letters.

In The Last Decade

Hengjun He

8 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hengjun He United States 7 209 204 190 73 59 8 456
Giovanna Navarra Italy 9 145 0.7× 273 1.3× 72 0.4× 23 0.3× 70 1.2× 16 475
E.Andrew Boyd United Kingdom 9 150 0.7× 216 1.1× 140 0.7× 34 0.5× 13 0.2× 13 560
Rigel T. Christian United States 3 108 0.5× 401 2.0× 119 0.6× 16 0.2× 20 0.3× 3 499
Pontus Forsell Sweden 16 347 1.7× 108 0.5× 73 0.4× 36 0.5× 51 0.9× 27 694
Faizy Ahmed United States 14 168 0.8× 207 1.0× 114 0.6× 23 0.3× 9 0.2× 36 495
Michael P. Endsley United States 12 165 0.8× 277 1.4× 58 0.3× 35 0.5× 78 1.3× 14 610
Asha Subramanian India 6 50 0.2× 182 0.9× 114 0.6× 21 0.3× 18 0.3× 7 355
Hongfeng Deng United States 11 254 1.2× 798 3.9× 498 2.6× 144 2.0× 19 0.3× 15 1.1k
Olivier Finance France 9 89 0.4× 138 0.7× 118 0.6× 15 0.2× 6 0.1× 10 387
Niina Aaltonen Finland 11 145 0.7× 184 0.9× 71 0.4× 29 0.4× 18 0.3× 19 352

Countries citing papers authored by Hengjun He

Since Specialization
Citations

This map shows the geographic impact of Hengjun He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hengjun He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hengjun He more than expected).

Fields of papers citing papers by Hengjun He

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hengjun He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hengjun He. The network helps show where Hengjun He may publish in the future.

Co-authorship network of co-authors of Hengjun He

This figure shows the co-authorship network connecting the top 25 collaborators of Hengjun He. A scholar is included among the top collaborators of Hengjun He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hengjun He. Hengjun He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
2.
Yuan, Yunyun, Li Guo, Hengjun He, et al.. (2011). Characterization of 6α- and 6β-N-Heterocyclic Substituted Naltrexamine Derivatives as Novel Leads to Development of Mu Opioid Receptor Selective Antagonists. ACS Chemical Neuroscience. 2(7). 346–351. 34 indexed citations
3.
Guo, Li, et al.. (2008). 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: Design, synthesis, and biological studies. Bioorganic & Medicinal Chemistry Letters. 19(6). 1825–1829. 20 indexed citations
4.
Liu, Yunguang, Kathleen Wallis, Michaela Egertová, et al.. (2007). CB1 Cannabinoid Receptor Activity Is Modulated by the Cannabinoid Receptor Interacting Protein CRIP 1a. Molecular Pharmacology. 72(6). 1557–1566. 107 indexed citations
5.
Paugh, Steven W., Michael P. Cassidy, Hengjun He, et al.. (2006). Sphingosine and Its Analog, the Immunosuppressant 2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, Interact with the CB1 Cannabinoid Receptor. Molecular Pharmacology. 70(1). 41–50. 56 indexed citations
6.
Huffman, John W., Dana E. Selley, Hengjun He, et al.. (2005). 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorganic & Medicinal Chemistry Letters. 15(18). 4110–4113. 106 indexed citations
7.
Huffman, John W., Dana E. Selley, Hengjun He, et al.. (2005). 1‐Pentyl‐3‐phenylacetylindoles, a New Class of Cannabimimetic Indoles.. ChemInform. 36(49). 5 indexed citations
8.
Gao, Ning, Liqin Shen, Zhuo Zhang, et al.. (2003). Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Molecular and Cellular Biochemistry. 255(1-2). 33–45. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026